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Abstract
Background: Esophageal variceal bleeding (EVB) is a serious and common complication of cirrhosis. Diabetes
mellitus (DM) and chronic kidney disease (CKD) increase mortality in patients with cirrhosis. However, whether
coexisting DM and CKD increase mortality in cirrhotic patients with EVB remains unclear.
Methods: We enrolled cirrhotic patients hospitalized with the first presentation of EVB from 2005 through 2010
using Longitudinal Health Insurance Database 2005. The hazard ratios (HRs) of 42-day and one-year EVB mortality
were calculated using Cox regression model.
Results: We identified 888 patients hospitalized with the first presentation of EVB. Among the cirrhotic patients
with EVB, all-cause mortality at 42-day and one-year were 21.3 and 45.0 %, respectively. The respective HRs for the
42-day and one-year mortality were 1.80 (95 % confidence interval [CI], 1.10–2.97) and 1.52 (95 % CI, 1.06–2.17) for
patients with CKD and 0.79 (95 % CI, 0.57–1.10) and 0.88 (95 % CI, 0.71–1.09) for patients with DM. Specifically,
coexisting CKD and DM increased the 42-day and one-year mortality with respective HRs of 1.99 (95%CI, 1.03–3.84)
and 1.84 (95%CI, 1.14–2.98) compared with those without CKD and DM. The HRs for 42-day and 1-year mortality in
female patients with DM and CKD were 4.03 (95%CI, 1.40–11.59) and 2.84 (95%CI, 1.31–6.14) respectively, and were
2.93 (95%CI, 1.14–7.57) and 2.42 (95%CI, 1.28–4.57) in male patients with DM and CKD.
Conclusion: We identified that coexisting DM and CKD increased risk of mortality at 42 days and 1 year following EVB.
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Background
Bleeding from esophageal varices is a life-threatening
condition with an annual mortality of 57 %. Nearly half
these deaths occur within 6 weeks from the initial epi-
sode of bleeding [1]. Various factors have been proposed
as predictors of outcome of variceal bleeding, some of
which include age, gender, stage of cirrhosis, etiology,
and associated conditions like renal failure and diabetes
mellitus (DM) [2–5].
Renal function is a critical prognostic factor in cirrhotic
patients with esophageal variceal bleeding (EVB) [6, 7].
Patients with chronic kidney disease (CKD) have many
long-term complications, such as increased immuno-
compromised status [8], as well as an increased risk of
metabolic disorders [9], and cardiovascular events [10].
Physiological mechanisms contributing to an increased
bleeding tendency included uremic platelet dysfunction,
use of antiplatelet agents, and anticoagulants [11, 12].
In addition, usage of aspirin is associated with the oc-
currence of EVB in cirrhotic patients [13].
The Verona Diabetes Study, a population-based study
with 7,148 patients with DM, showed an increased risk
of mortality from chronic liver disease and cirrhosis com-
pared with the general population [14]. Insulin resistance,
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a characteristic feature of DM, has been proven to be a
predictor of portal hypertension [15] and the development
of esophageal varices [16]. In a hospital-based study with
146 patients with cirrhosis, DM significantly correlated
with gastroesophageal variceal bleeding [2].
The presence of metabolic syndrome and the number
of metabolic syndrome components have been associated
with higher prevalence of CKD [9]. CKD is one of the
most common long-term complications of DM [17]. The
prevalence of DM and CKD in Taiwan has been reported
as 7,570 and 892 per 100,000 population, respectively
[18, 19]. How DM and/or CKD per se, is/are independ-
ent mortality risk factors, and how they further increase
the risk of mortality is still unclear. This study aimed to
investigate DM and CKD on mortality of cirrhotic pa-
tients with first presentation of EVB.
Methods
Data source
This retrospective cohort study used data from the Lon-
gitudinal Health Insurance Database 2005 (LHID2005),
which is a subset of the National Health Insurance Re-
search Database (NHIRD). The LHID2005 database was
derived by the Bureau of National Health Insurance, Min-
istry of Health and Welfare of Taiwan and maintained by
the National Health Research Institutes so as to make it ac-
cessible for research purposes. The LHID2005 is broadly
used in academic studies [20–23]. LHID2005 contains all
the original claims data of one million out of 23 million
National Health Insurance enrollees, randomly sampled
from the year 2005 registry for beneficiaries of the NHIRD.
There was no significant difference in the age and sex
distribution between patients in the LHID2005 and the
original NHIRD [24]. The use of the data was reviewed
and granted by the National Health Research Institutes.
The source data was encrypted and the data extracted
was anonymous. This study was approved by the Insti-
tutional Review Board of the Chung-Shan Medical Uni-
versity Hospital, Taiwan.
Patient identification
This retrospective study included cirrhotic patients who
were hospitalized with a first presentation of EVB be-
tween 2005 and 2010. Subjects with incomplete informa-
tion, such as sex and registry data were excluded. EVB
was confirmed by the International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM)
code (ICD-9-CM code 456.0 and 456.20) and esophageal
variceal ligation or sclerotherapy.
Variables of exposure
To reduce bias, the diagnoses of comorbidities were
confirmed by more than two outpatient visits or one ad-
mission in 1 year. Comorbidities were defined using the
following ICD-9-CM codes: DM (250), CKD (585 and
586), hepatitis B virus (HBV) infection (070.2, 070.3, and
V02.61), hepatitis C virus (HCV) infection (070.41, 070.44,
070.51, 070.54, 070.7, and V02.62), alcohol-related
disorders (291, 303, 305.00–305.03, and 571.0–571.3),
hepatocellular carcinoma (HCC) (155.0 and 155.2), as-
cites (789.5 or ICD-9 Volume 3 procedure code 54.91),
hepatic encephalopathy (572.2), spontaneous bacterial
peritonitis (SBP) (567.2, 567.8, or 567.9, excluding the
procedure codes for the abdominal surgery), chronic
obstructive pulmonary disease (COPD) (490, 491, 492,
494, and 496), asthma (493), pulmonary tuberculosis (TB)
(010 - 012), acute coronary syndrome (410–414)), cere-
brovascular accident (430–438), and bacterial infections.
The bacterial infections during hospitalization included
pneumonia (ICD-9-CM 481–487, excluding 484), liver
abscess (ICD-9-CM 572.0), empyema (ICD-9-CM 510),
cellulitis (ICD-9-CM 681 and 682), necrotizing fasciitis
(ICD-9-CM 728.86), central nervous system infection
(ICD-9-CM 324 and 320), sepsis (ICD-9-CM 038 and
790.7), infective endocarditis (ICD-9-CM 421), urinary
tract infection (ICD-9-CM 590.1, 595.0, 595.9, and 599.0),
biliary tract infection (ICD-9-CM 574.00, 574.01, 574.30,
574.31, 574.60, 574.61, 574.80, 574.81, 575.0, and 576.1),
septic arthritis (ICD-9-CM 711), and perianal abscess
(ICD-9-CM 566).
Statistical analysis
All analyses were made using SAS 9.3 software (SAS
Institute, Cary, NC). Chi square test was used to exam
the differences in sociodemographic characteristics and
comorbidities. Multivariate Cox proportional hazards
regression was performed to determine mortality for
independent variables, such as sex, age, low income,
urbanization, comorbidities, etiology, and complications of
cirrhosis. Furthermore, in order to evaluate the effect of
coexisting DM and CKD on all-cause mortality, 4 separate
models were conducted: 42-day mortality of all patients
(Model 1), 42-day mortality stratified by gender (Model 2),
1-year mortality of all patients (Model 3), and 1-year mor-
tality stratified by gender (Model 4). All comparisons with
a p-value < 0.05 were considered statistically significant.
Results
The demographic characteristics and comorbidities of cir-
rhotic patients with EVB are listed in Table 1. The 42-day
and 1-year EVB mortalities were 21.3 and 45.0 %, respect-
ively. HBV, CKD, HCC, and hospitalization due to ascites,
hepatic encephalopathy, and SBP were more common
in non-survivors. The possible etiologies of CKD were
as follows: diabetes alone, 3 cases (4.6 %), diabetes +
hypertension, 8 (12.3 %), diabetes + hypertension + coronary
artery disease, 2 (3.1 %), diabetes + hypertension +
hyperlipidemia, 2 (3.1 %), diabetes + hypertension +
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Table 1 Characteristics of cirrhotic patients with first esophageal variceal bleeding and mortality, Taiwan, 2005–2010
42-day mortality One-year mortality
Survivors
(n = 699) (%)
Death (n = 189) (%) p-value Survivors
(n = 488) (%)
Death (n = 400) (%) p-value
Year of first diagnosis of EVB
2005 (n = 167) 132 (18.9) 35 (18.5) 0.909 84 (17.2) 83 (20.8) 0.585
2006 (n = 151) 122 (17.4) 29 (15.3) 0.808 84 (17.2) 67 (16.8) 0.864
2007 (n = 142) 101 (14.4) 41 (21.7) 0.170 72 (14.8) 70 (17.5) 0.686
2008 (n = 134) 102 (14.6) 32 (16.9) 0.769 79 (16.2) 55 (13.7) 0.729
2009 (n = 146) 120 (17.2) 26 (13.8) 0.648 83 (17.0) 63 (15.7) 0.864
2010 (n = 148) 122 (17.5) 26 (13.8) 0.615 86 (17.6) 62 (15.5) 0.793
Sex
Female (n = 243) 202 (28.9) 41 (21.7) 0.049 151 (30.9) 92 (23.0) 0.008
Age at the first diagnosis of EVB
< 50 (n = 261) 212 (30.3) 49 (25.9) 0.433 165 (33.8) 96 (24.0) 0.002
50–69 (n = 437) 335 (47.9) 102 (54.0) 0.302 230 (47.1) 207 (51.8) 0.171
≥70 (n = 190) 152 (21.8) 38 (20.1) 0.626 93 (19.1) 97 (24.2) 0.061
Complication of cirrhosis
HCC (n = 359) 247 (35.3) 112 (59.3) <0.001 127 (26.0) 232 (58.0) <0.001
Infection during hospitalization (n = 58) 40 (5.7) 18 (9.5) 0.061 26 (5.3) 32 (8.0) 0.109
Previous episodes of decompensation required
hospitalization within 1 year before EVB
Ascites
0 (n = 711) 577 (82.6) 134 (70.9) <0.001 417 (85.4) 294 (73.5) <0.001
1 (n = 114) 82 (11.7) 32 (16.9) 0.058 52 (10.7) 62 (15.5) 0.038
≥ 2 (n = 63) 40 (5.7) 23 (12.2) 0.002 19 (3.9) 44 (11.0) <0.001
Hepatic encephalopathy
0 (n = 789) 628 (89.9) 161 (85.2) 0.247 447 (91.6) 342 (85.4) 0.026
1 (n = 60) 47 (6.7) 13 (6.9) 0.940 31 (6.4) 29 (7.3) 0.724
≥ 2 (n = 39) 24 (3.4) 15 (7.9) 0.041 10 (2.0) 29 (7.3) 0.001
SBP
0 (n = 846) 670 (95.9) 176 (93.1) 0.329 477 (97.8) 369 (92.3) <0.001
1 (n = 35) 28 (4.0) 7 (3.7) 0.850 10 (2.0) 25 (6.2) 0.003
≥ 2 (n = 7) 1 (0.1) 6 (3.2) <0.001 1 (0.2) 6 (1.5) 0.028
Etiology of cirrhosis
HBV (n = 340) 250 (35.8) 90 (47.6) 0.003 168 (34.4) 172 (43.0) 0.009
HCV (n = 306) 248 (35.5) 58 (30.7) 0.219 168 (34.4) 138 (34.5) 0.982
Alcoholism (n = 382) 313 (44.8) 69 (36.5) 0.042 236 (48.4) 146 (36.5) <0.001
Comorbidities
DM (n = 332) 270 (38.6) 62 (32.8) 0.142 187 (38.3) 145 (36.3) 0.526
CKD (n = 65) 43 (6.2) 22 (11.6) 0.010 23 (4.7) 42 (10.5) 0.001
COPD (n = 216) 174 (24.9) 42 (22.2) 0.448 124 (25.4) 92 (23.0) 0.405
Asthma (n = 87) 69 (9.9) 18 (9.5) 0.887 49 (10.0) 38 (9.5) 0.787
TB (n = 28) 24 (3.4) 4 (2.1) 0.358 18 (3.7) 10 (2.5) 0.313
Previous episode of acute coronary syndrome (n = 184) 145 (20.7) 39 (20.6) 0.974 96 (19.7) 88 (22.0) 0.395
Previous episode of cerebrovascular accident (n = 102) 73 (10.4) 29 (15.3) 0.061 45 (9.2) 57 (14.3) 0.019
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coronary artery disease + hyperlipidemia, 5 (7.7 %),
diabetes + other etiologies, 4 (6.1 %), and etiologies
other than diabetes, 41 (63.1 %). For CKD patients
with or without DM, the 42-day mortalities were 41.7 %
(10/24) and 29.3 % (12/41), and the 1-year mortality were
79.2 % (19/24) and 56.1 % (23/41), respectively (data not
shown).
Table 2 shows the HRs for 42-day and 1-year mortal-
ity. At 42 days following EVB, the risk of mortality was
high in patients with CKD (hazard ratio [HR], 1.80; 95 %
confidence interval [CI], 1.10–2.97], HCC (HR, 2.13;
95 % CI, 1.54–2.95), and previous hospitalization due to
ascites and SBP. Similarly, at 1 year following EVB, risk
of mortality was also high in men (HR,1.54; 95 % CI,
1.19–2.00), CKD (HR,1.52; 95 % CI, 1.06–2.17), HCC
(HR, 2.48; 95%CI, 1.99–3.10), infections during hospitalization
(HR:1.50; 95 % CI, 1.03–2.18), and previous hospitalization
due to ascites and SBP.
Table 3 illustrates the adjusted HRs of EVB mortality
at 42 days and 1 year in patients with either DM, CKD,
or both by gender. For 42-day mortality (Model 1), the
HRs were 1.99 (95 % CI, 1.03–3.84) and 0.72 (95%CI,
0.50–1.02) among DM patients with or without CKD,
respectively. The HR for patients with CKD was 1.25
(95 % CI, 0.62–2.52). When stratified by gender and
disease combinations (Model 2), the HRs were higher in
female diabetic patients with CKD (HR, 4.03; 95 % CI,
1.40–11.59) and male diabetic patients with CKD (HR,
2.93; 95 % CI, 1.14–7.57).
For 1-year mortality, the HRs were 1.84 (95 % CI,
1.14–2.98) and 0.80 (95 % CI, 0.64–1.02) in diabetic
patients with or without CKD (Model 3). The HR for
patients with CKD was 1.07 (95 % CI, 0.65–1.76). There
was significant interaction between DM and CKD (p =
0.028). In Model 4, the HRs for male and female diabetic
patients with CKD were 2.84 (95 % CI, 1.31–6.14) and
2.42 (95 % CI, 1.28–4.57), respectively.
Discussion
We found that coexistence of CKD and DM was inde-
pendently associated with 42-day and 1-year mortality in
both sexes. These risk factors are easy to identify follow-
ing the initial EVB event and are valuable for predicting
clinical outcomes. They may also be useful for guiding
the clinical management of cirrhotic patients with EVB.
Identifying patients at high risk will be important for
cost-effective management of EVB.
Globally, 57 % of cirrhosis is attributable to either
hepatitis B (30 %) or hepatitis C (27 %) [25]. Alcohol
consumption is another important cause, accounting for
about 20 % of the cases. The seroprevalence of HBV and
HCV was 17.3 and 4.4 % in Taiwan, respectively [26].
More than 70 % of cirrhosis and HCC were the sequelae
of chronic HBV infection in 1990s [27]. Our results
showed that HBV infection was higher in non-survivors
and the prevalence of HBV infection in HCC was 46.2 %.
When HBV infection was put into the multivariate model
for analyses, there was no significant association between
HBV infection and EVB mortality. The efficacy of univer-
sal immunization has been proven with substantial reduc-
tions of HBV carriage in children, adolescents and young
adults since 1984 [28]. HCC in Taiwan also falls after uni-
versal hepatitis B vaccination [29]. We also showed im-
provement in the 42-day mortality rate over time perhaps
due to treatment advances, such as variceal ligation, ap-
propriate vasoconstrictor usage, and antiviral treatment
for the underlying cirrhosis [30, 31].
Bleeding from ruptured esophageal varices is the most
severe complication of cirrhosis and 6-week mortality
rates have been reported to be 15–20 % [30]. The in-
patient bleeding rate among cirrhotic patients has been
reported as 13 % [32]. Around 30 to 60 % of cirrhotic
patients suffer from DM with insulin resistance and
hyperinsulinemia [33]. The presence of DM appears to
be associated with failure to control esophageal variceal
bleeding and re-bleeding [34]. Hyperglycemia induces
splanchnic hyperemia, increases portal pressure and azy-
gos vein blood flow, and may increase the risk of variceal
bleeding [35, 36]. However, in this study, DM individually
failed to show significant association with 42-day and
1-year mortality.
In an analysis involving 2,592 cirrhotic patients hospi-
talized with SBP in 2004, the respective HRs for 30-day
and 1-year mortality were 1.37 (95%CI, 0.85–2.21) and
1.37 (95%CI, 1.01–1.84) in patients with CKD [37]. In-
creased long-term mortality rates of SBP in cirrhotic
Table 1 Characteristics of cirrhotic patients with first esophageal variceal bleeding and mortality, Taiwan, 2005–2010 (Continued)
Low income
Yes (n = 24) 20 (2.9) 4 (2.1) 0.575 7 (1.4) 17 (4.3) 0.010
Urbanization
Urban (n = 438) 339 (48.5) 99 (52.4) 0.357 246 (50.4) 192 (48.0) 0.475
Normal (n = 316) 243 (34.8) 73 (38.6) 0.357 160 (32.8) 156 (39.0) 0.120
Rural (n = 134) 117 (16.7) 17 (9.0) 0.030 82 (16.8) 52 (13.0) 0.214
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, EVB esophageal variceal bleeding, HBV hepatitis B virus,
HCC hepatocellular carcinoma, HCV hepatitis C virus, SBP spontaneous bacterial peritonitis, TB pulmonary tuberculosis
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patients may be attributed to the impaired immune
functions caused by CKD [38]. Hung et al. evaluated
4,932 cirrhotic patients with hepatic encephalopathy and
showed that the adjusted HR of 3-year mortality for
CKD was 1.93 (95 % CI, 1.55–2.40) compared with those
with normal renal function [39]. However, patients with
end-stage renal disease (ESRD) receiving hemodialysis
had better 3 year survival rate (HR, 0.66; 95 % CI,
0.46–0.94) than those with CKD. This implied that CKD
may be associated with poor clearance of circulatory
neurotoxic substances that increases the susceptibility to
mortality in cirrhotic patients with hepatic encephalop-
athy. Hung et al. evaluated 6,740 cirrhotic patients who
were hospitalized with EVB in 2007 and showed that
Table 2 Estimation of hazard ratios of mortality in patients with esophageal variceal bleeding between 2005 and 2010 using cox
proportional model
42-day mortality One-year mortality
HR 95 % C.I. p-value HR 95 % C.I. p-value
Sex (reference: Female)
Male 1.37 0.93–2.02 0.109 1.54 1.19–2.00 0.001
Age at the first diagnosis of EVB (reference: <50)
50–69 0.93 0.63–1.38 0.721 1.03 0.77–1.38 0.831
≥ 70 0.77 0.45–1.34 0.361 1.24 0.85–1.81 0.269
Comorbidities
DM 0.79 0.57–1.10 0.163 0.88 0.71–1.09 0.241
CKD 1.80 1.10–2.97 0.021 1.52 1.06–2.17 0.023
COPD 0.88 0.59–1.31 0.533 0.85 0.65–1.12 0.251
Asthma 1.19 0.70–2.00 0.526 1.08 0.75–1.55 0.699
TB 0.68 0.27–1.88 0.460 0.65 0.34–1.24 0.191
Previous episode of acute coronary syndrome 1.01 0.68–1.51 0.954 1.04 0.79–1.36 0.779
Previous episode of cerebrovascular accident 1.54 0.99–2.38 0.054 1.21 0.89–1.65 0.214
Etiology of cirrhosis
HBV 1.13 0.82–1.54 0.465 1.07 0.86–1.33 0.559
HCV 0.81 0.57–1.14 0.224 0.86 0.68–1.09 0.217
Alcoholism 0.76 0.52–1.11 0.157 0.74 0.57–0.97 0.031
Complication of cirrhosis
HCC 2.13 1.54–2.95 <0.001 2.48 1.99–3.10 <0.001
Infection during hospitalization 1.65 0.99–2.75 0.055 1.50 1.03–2.18 0.035
Previous episodes of decompensation required hospitalization within 1 year before EVB
Ascites (reference: 0)
1 1.66 1.10–2.52 0.017 1.60 1.18–2.18 0.003
≥ 2 1.77 1.04–3.02 0.036 1.73 1.18–2.55 0.005
Hepatic encephalopathy (reference: 0)
1 0.98 0.54–1.79 0.949 1.09 0.72–1.67 0.680
≥ 2 1.09 0.59–1.99 0.793 1.28 0.82–1.99 0.271
SBP (reference: 0)
1 0.63 0.28–1.41 0.258 1.20 0.76–1.92 0.435
≥ 2 3.42 1.38–8.50 0.008 2.93 1.24–6.93 0.015
Low income 0.70 0.25–1.99 0.503 1.63 0.95–2.79 0.078
Urbanization (reference: Urban)
Sub-urban 1.02 0.75–1.39 0.891 1.09 0.87–1.35 0.455
Rural 0.58 0.34–0.98 0.043 0.84 0.61–1.15 0.270
CI confidence interval, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, EVB esophageal variceal bleeding,
HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, HR hazard ratio, SBP spontaneous bacterial peritonitis, TB pulmonary tuberculosis
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ESRD was associated with 1-year mortality (HR,1.50;
95 % CI, 1.18–1.91), but not a risk factor for 42-day
mortality (HR,1.19; 95 % CI, 0.79–1.78) [5]. They impli-
cated that the ESRD-related platelet dysfunction con-
tributed higher EVB and mortality. In our study, we
identified that CKD was independent prognostic factor
for both 42-day and one-year mortality in cirrhotic pa-
tients with first presentation of EVB.
Coexisting DM and CKD are important prognostic
factors in cirrhotic patients regardless of the causes of
liver diseases. CKD and DM have many long-term com-
plications such as increased immunocompromised status,
as well as increased risk of metabolic disorders and cardio-
vascular events [40–42]. DM increases portal blood flow
secondary to fluctuating blood sugar levels leading to an
increase in portal pressure [35, 43]. There is increased
bleeding tendency due to uremic platelet dysfunction,
use of antiplatelet agents, and anticoagulants [11, 12].
In addition, usage of aspirin increases the occurrence of
EVB in cirrhotic patients [13]. These complications
could indicate why the 42-day and 1-year overall mor-
tality was higher among the coexisting DM and CKD
than DM or CKD individuals. A gender-stratified com-
parative analysis indicated that coexisting DM and
CKD exhibited mortality risk in both genders.
In a cohort study with patients with chronic hepatitis
C (CHC), patients with new-onset diabetes subsequently
were found to have an increased risk of developing cir-
rhosis, or decompensation in those with established cir-
rhosis [44]. Persico et al. retrospectively evaluated 852
consecutive patients (726 CHC and 126 chronic hepatitis
B) who had undergone liver biopsy [45]. Liver fibrosis
(odds ratio [OR], 4.70; 95%CI, 2.75–8.03) was independ-
ent risk factors for the presence of significant steatosis
(>30 %) in patient with CHC. Camma et al. analyzed 104
patients with CHC cirrhosis (Child-Pugh class A) receiv-
ing upper gastrointestinal endoscopy [16]. They found a
high homeostasis model assessment score (OR, 1.37;
95 % CI, 1.01–1.86) as an independent predictor of the
presence of esophageal varices. Cirrhosis, per se, inde-
pendently by the viral etiology, may be associated with
the development of insulin resistance and diabetes.
Although HCV and HBV infection were not associated
with increased risk of mortality, they have been reported
to be associated with renal diseases. HCV is also associ-
ated with extra-hepatic diseases, including various types
of glomerulonephritis, even in the absence of cirrhosis
[46]. A high baseline HCV viral load was an independent
predictor of CKD [47]. Soma et al. indicated that HCV
infection leads to a rapid decline in the renal function of
Table 3 Adjusted Risk for 42-Day and One-Year Mortality Stratified by DM, Chronic Kidney Diseases, and Sex
42-day mortality One-year mortality
Model 1a Model 2b Model 3a Model 4b
HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value
All patients
Non-DM & CKD Ref. Ref.
Only DM 0.72 0.50–1.02 0.062 0.80 0.64–1.02 0.066
Only CKD 1.25 0.62–2.52 0.541 1.07 0.65–1.76 0.801
DM + CKD 1.99 1.03–3.84 0.042 1.84 1.14–2.98 0.012
P for DM × CKD interaction 0.100 0.028
Women
Non-DM & CKD Ref. Ref.
Only DM 1.11 0.56–2.21 0.772 0.77 0.49–1.21 0.260
Only CKD 3.40 0.75–15.48 0.113 1.30 0.39–4.28 0.672
DM + CKD 4.03 1.40–11.59 0.010 2.84 1.31–6.14 0.008
Men
Non-DM & CKD 2.00 1.14–3.52 0.016 1.61 1.13–2.29 0.009
Only DM 1.25 0.67–2.32 0.487 1.32 0.90–1.92 0.154
Only CKD 2.02 0.83–4.94 0.123 1.64 0.90–2.98 0.108
DM + CKD 2.93 1.14–7.57 0.026 2.42 1.28–4.57 0.007
P for gender × diseases interaction 0.920 0.559
CI confidence interval, CKD chronic kidney disease, DM diabetes mellitus, HR hazard ratio, Ref reference
aAdjusted for sex, age, comorbidities, etiology of cirrhosis, complications of cirrhosis, low income and urbanization
bAdjusted for age, comorbidities, etiology of cirrhosis, complications of cirrhosis, low income and urbanization
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patients with diabetic nephropathy [48]. HBV-related
renal injury is associated with the deposition of immune
complexes of HBV antigens and host antibodies [49].
Untreated chronic HBV infection is also associated with
increased risk of CKD [50].
Hepatic steatosis or fatty liver is characterized by lipid
accumulation within the cytoplasm of hepatocytes, and
includes a spectrum of liver disease from a benign sim-
ple steatosis, steatohepatitis, to fibrosis [51]. In Taiwan,
the prevalence of non-alcoholic fatty liver disease (NAFLD)
is about 11.5 % [52], and the rates are higher in subgroups,
from 66.4 % in healthy taxi drivers [53] to 80 % in obese in-
dividuals enrolled in weight reduction programs [54]. In a
cross-sectional community study that included 11.4 %
(372/3,260) individuals with elevated alanine aminotransfer-
ase (ALT), NAFLD was the most common cause of ALT
elevation with a prevalence of 33.6 %, and followed by HBV
(28.5 %), unexplained cause (21.8 %), HCV (13.2 %), both
HBV and HCV (2.2 %), and excess alcohol consumption
(0.8 %) [55]. Approximately 1 % of patients with NAFLD
develop cirrhosis [56], where as in non-alcoholic steatohe-
patitis (NASH), the estimated figure is up to 20 % [57].
However, NAFLD was not available in the NHIRD.
Our data included all EVB patients hospitalized in a
variety of hospitals in Taiwan; hence, selection bias was
minimized. There were some significant limitations to
this study. First, the basic laboratory data (e.g. prothrom-
bin times, bilirubin, creatinine, and albumin levels) were
not available. For the severity of cirrhosis, Child-Pugh or
Model of End-Stage Liver Disease (MELD) scores could
not be calculated using the ICD-9 coding in the data-
base. We put previous episodes of decompensation that
required hospitalization, such as asictes, hepatic enceph-
alopathy, and SBP into multiple variable analyses. This
information could obviate the important limitation of not
having laboratory data to calculate the MELD score.
Second, the exact cases of NAFLD-related cirrhosis were
not available. Data on NAFLD-related cirrhosis are limited
and only one case report has been reported in Taiwan
[58]. Third, the diagnoses of EVB and other comorbidities
were based on ICD-9 codes, and misclassification could
be possible. We included cirrhotic patients who were
hospitalized with first presentation of EVB and received
esophageal variceal ligation or sclerotherapy to minimize
ascertainment bias.
Conclusions
This study provides evidence that coexistence of CKD
and DM has a higher impact on 42-day and one-year
mortality than DM or CKD individually.
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